DULAGLUTIDE

Brand name:

• Trulicity®

Pharmaceutical company:

Eli Lilly Australia Pty Ltd

Condition/indication:
(therapeutic use)

• Type 2 diabetes mellitus

PBAC Submission type:

New listing (–)

Comment:

--

Public Summary Document:

PBAC Public Summary Documents – March 2022

Related medicines:

--

Submission received for:

March 2022 PBAC meeting

Opportunity for consumer comment:

Open 24/11/2021 and close 27/01/2022 (see PBS Website)

PBAC meeting:

Held on 09/03/2022

PBAC outcome published:

Deferred (see PBAC Outcomes)

Lodgement of required documentation:

Not applicable

Agreement to listing arrangements:

Not applicable

Government processes:

Not applicable

Medicine listed on the PBS:

Not applicable

---